title: Clinical utility of type 1 growth factor receptor expression in colon cancer.
abstract: BACKGROUND
  To evaluate the expression pattern and prognostic significance of the type 1 growth factor receptor (T1GFR) family in colon carcinoma.
  
  
  METHODS
  Tissue microarrays were constructed using 127 tumor samples and 47 metastatic lymph nodes and T1GFR family expression was determined by immunohistochemistry. Univariate and multivariate analyses examined clinicopathologic variables for prognostic significance, and the correlation between primary and lymph node expression was determined by Spearman correlation.
  
  
  RESULTS
  Overexpression of HER-1, HER-2, HER-3, and HER-4 in tumor samples was 32%, 1%, 12%, and 37%, respectively, and 30%, 0%, 11%, and 24% in nodal samples, respectively. On multivariate analysis, positive margins, lymphatic invasion, and HER-3 expression were significant predictors of survival outcome. There was significant correlation between tumor and regional lymph node expression for the T1GFR family members. Tumor HER-3 expression was associated with lymphatic invasion and distant recurrence.
  
  
  CONCLUSIONS
  Tumor HER-3 expression has prognostic utility in individuals with colon carcinoma. Correlation between tumor and lymph node expression of T1GFR family members suggests that tumor receptor status may guide targeted therapy selection.
authors.affiliation: Department of Surgery, St.Paul's Hospital, Vancouver, British Columbia, Canada.
authors.forename: Sher-Ping
authors.initials: SP
authors.lastname: Leung
authors.forename: Obi L
authors.initials: OL
authors.lastname: Griffith
authors.forename: Hamid
authors.initials: H
authors.lastname: Masoudi
authors.forename: Allen
authors.initials: A
authors.lastname: Gown
authors.forename: Steven
authors.initials: S
authors.lastname: Jones
authors.forename: Terry
authors.initials: T
authors.lastname: Phang
authors.forename: Sam M
authors.initials: SM
authors.lastname: Wiseman
mesh_terms: D000230:Adenocarcinoma / Q000378:metabolism*; D000328:Adult; D003110:Colonic Neoplasms / Q000378:metabolism* / Q000401:mortality / Q000473:pathology; D066246:ErbB Receptors / Q000378:metabolism*; D005260:Female; D006801:Humans; D007150:Immunohistochemistry; D008198:Lymph Nodes / Q000378:metabolism; D008207:Lymphatic Metastasis; D008297:Male; D008875:Middle Aged; D015999:Multivariate Analysis; D011379:Prognosis; D018719:Erb-b2 Receptor Tyrosine Kinases / Q000378:metabolism; D020893:Receptor, ErbB-3 / Q000378:metabolism; D066247:Receptor, ErbB-4; D017978:Receptors, Growth Factor / Q000378:metabolism*; D016019:Survival Analysis
chemical_list: D066246:ErbB Receptors; D018719:Erb-b2 Receptor Tyrosine Kinases; D020893:Receptor, ErbB-3; D066247:Receptor, ErbB-4; D017978:Receptors, Growth Factor; C512478:EGFR protein, human; C508053:ERBB2 protein, human; C587689:ERBB4 protein, human